• No results found

[PDF] Top 20 <p>The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy</p>

Has 10000 "<p>The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy</p>" found on our website. Below are the top 20 most common "<p>The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy</p>".

&lt;p&gt;The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy&lt;/p&gt;

<p>The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy</p>

... years, immunotherapy targeting immune checkpoints has shed a light on cancer ...of cancer treatment by inhibiting the immune checkpoint programmed cell death protein 1 (PD-1) and ... See full document

9

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

... of PD-L1 expression on tumors were assessed from Nogu- chi et ...of PD-L1. They found that abnormally high expression of PD-L1, but not levels of PD-L1 expres- sion ... See full document

8

New emerging targets in cancer immunotherapy: the role of TIM3

New emerging targets in cancer immunotherapy: the role of TIM3

... Figure 1 Role of ...on Treg, which in turn inhibit effector T cell ...immune function. L1/L2, ligand 1/2; mAb, monoclonal antibody; PD, programmed death; TIL, ... See full document

5

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

... anti- PD-1/PD-L1 therapy is unclear. The PD-1/PD-L1 axis is a critical pathway for maintaining immune homeostasis ...in cancer immune eva- sion, [16] ... See full document

10

PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

... tumor development by restoring the functions of T cells to kill the tumor cells, and the quan- tity of TILs plays an important role in the immunotherapy ...with PD-L1/ ... See full document

13

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

... of PD-L1 in various cancer cells ...that PD-L1 expression in melanoma cells is mainly regulated by the IFN-γ receptor signaling pathway which subsequently converged to the binding of ... See full document

13

&lt;p&gt;Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis&lt;/p&gt;

<p>Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis</p>

... death 1 (PD-1) receptor has emerged as a dominant negative regulator of antitumor T-cell effector function when engaged by its ligand pro- grammed cell death ligand 1 ... See full document

13

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

... the PD-1/PD-L1 axis results in antitumor activ- ity due to its ability, in part, to inhibit interferon-induced adaptive immune resistance characterized by interferon- induced JAK-STAT ... See full document

18

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

... the PD-1/PD-L1 axis molecules, the local TME may be a key site for identifying predictive biomarkers for PD-1 pathway ...of PD-L1 in tumor-infiltrating im- ... See full document

25

&lt;p&gt;Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle&lt;/p&gt;

<p>Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle</p>

... a role in immunosuppressive function by releasing IL-10, TGF- β , and some other cyto- kines and protecting tumor cells from NK cells and T ...pancreatic cancer reduced the frequency of TAMs, ... See full document

12

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients

... and PD-L2 expression are up-regulated in a variety of human cancer ...types. PD-L1 is frequently expressed in several types of solid tumor cells, whereas PD-L2 is highly expressed in ... See full document

12

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo

... K7M2 cells treated with lentiviral transfection were sus- pended and cultured in a 6-well plate. After 12 h, the CD4 + PD-1 + lymphocyte were co-cultured with K7M2 cells. The cells were then divided into ... See full document

11

Targeting PD-1/PD-L1 in lung cancer: current perspectives

Targeting PD-1/PD-L1 in lung cancer: current perspectives

... positive PD-L1 tumors in 40%–50% of NSCLC ...use 1% as a cut-off, but most also test other cut-off points for defining “negative”, “light positive”, and “intense positive” patients (over a cut-off of ... See full document

16

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy

... for PD-L1 positivity using four different PD-L1 IHC assays, 22C3, 28-8, SP263 and ...detect PD-L1 expression on tumor cells, whereas SP142 showed less stained tumor ...for ... See full document

12

PD-L1 expression in human cancers and its association with clinical outcomes

PD-L1 expression in human cancers and its association with clinical outcomes

... Table 1 summarizes the studies on the prognostic value of PD-L1 in different ...pancreatic cancer (PC), gastric cancer, RCC, esophageal cancer (EC), and ovarian cancer can ... See full document

17

CD84 regulates PD 1/PD L1 expression and function in chronic lymphocytic leukemia

CD84 regulates PD 1/PD L1 expression and function in chronic lymphocytic leukemia

... of PD-L1/PD-1 expression by ...regulates PD-L1 expression and T cell function in cells derived from patients with ...and PD-L1 cell-surface expression levels ... See full document

15

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

... lung cancer was recently com- pleted. In the Blueprint PD-L1 IHC Assay Comparison Project, the Pathology Committee of the International Association for the Study of Lung Cancer joined efforts ... See full document

6

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

... no PD-1 or PD-L1 inhibitors have received marketing approval from the Chinese Food and Drug Administration ...January 1, 2013 and April 6, 2017, ...using PD-1/ ... See full document

8

Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.

Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.

... clinical development, PARP inhibitors are most studied and are now licensed for clinical use in ovarian cancer (Brown et al, ...its role in DNA repair, PARP has a well-established pro-inflammatory ... See full document

41

Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma

Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma

... University Cancer Center (Guangzhou, China) were ...on Cancer (AJCC, 2002) TNM staging ...University Cancer Center and was performed according to the Declaration of ... See full document

12

Show all 10000 documents...